Therefore, we concluded that SRD5A3 and IGF2BP3 play oncogenic roles in bladder tumorigenesis, and IGF2BP3 directly interacts with SRD5A3 mRNA and increases its stability during cisplatin resistance development in bladder cancer. This evidence concerns the gene IGF2BP3 and urinary bladder cancer.